Noticias

基于si-PRMT6的脓毒症-ARDS的治疗应用

Resumen de: CN121243384A

本发明属于生物医药技术领域，提供了PRMT6的新用途，具体是其抑制剂PRMT6抑制剂在制备预防或治疗治疗脓毒症‑ARDS药物中的应用。本发明首次公开了PRMT6作为脓毒症‑ARDS治疗靶点的应用价值。通过靶向抑制PRMT6的表达，可有效抑制肺泡上皮细胞（AECs）内的铁死亡，进而改善了ARDS相关的组织病理学，从而有效改善疾病进展，为脓毒症‑ARDS的靶向治疗开辟了新路径。

药物载体、纳米载药颗粒及制备方法和应用

Resumen de: CN121243406A

本发明属于药物递送技术领域，具体公开了药物载体、纳米载药颗粒及制备方法和应用。本发明利用天然多酚驱动的多种分子间相互作用，制备的药物载体具有良好的稳定性、生物安全性、生物活性和引人注目的扩展载药谱，可以负载疏水性和亲水性药物。与单纯的人血清白蛋白相比，本发明的药物载体负载效率最高提高96%，实现载体的高载药量和载药普适性。

改性多糖的水微球在促进伤口皮肤再生和抑制伤口皮肤纤维化中的应用

Resumen de: CN121243214A

本发明公开了改性多糖的水微球在促进伤口皮肤再生和抑制伤口皮肤纤维化中的应用。本发明中，通过与作为对照的Control组（硅油）和未改性的多糖的水微球组（AVBEC）相比，改性多糖的水微球组（AVBER）外用于深Ⅱ级烫伤模型巴马小型猪皮肤时，能够有效促进创面愈合，控制炎症程度和持续时间，调节细胞外基质组成和可塑性，降低纤维化标志蛋白的表达，达到促进皮肤再生和抑制纤维化的双重效果。解决了天然提取物和普通多糖微球产品生物活性低和稳定性差问题，发现改性后多糖的新功能。

一种向巨噬细胞高效递送核酸的脂质纳米颗粒复合物

Resumen de: CN121243111A

本发明公开了一种向巨噬细胞高效递送核酸的脂质纳米颗粒复合物。该复合包括40~70% 可电离阳离子脂质、5~15% 辅助脂质、18~50% 胆固醇和1~2% PEG化脂质。该脂质纳米颗粒复合物采用微流控设备进行制备，制备的脂质纳米颗粒复合物粒径在50~200nnm范围内，PDI小于0.3，粒度分布均一，能够将核酸药物高效递送至巨噬细胞内。

一种用于治疗阴经癌的中药复方靶向纳米制剂及制备方法

Resumen de: CN121243315A

本发明公开了一种用于治疗阴经癌的中药复方靶向纳米制剂及制备方法，该制剂由金银花、土茯苓、当归、黄芪、茯苓、牡丹皮、砂仁、半枝莲、白花蛇舌草、全蝎、水蛭和甘草等原料药经超临界CO2萃取与水提醇沉精制后，与磷脂、胆固醇、表面活性剂构成的纳米载体及叶酸‑PEG‑DSPE靶向配体结合制成。其制备方法包括中药有效部位群的提取、纳米脂质体的薄膜超声法制备、靶向修饰及冷冻干燥。本制剂通过叶酸受体介导的主动靶向作用，使药物特异性富集于肿瘤组织，具备粒径均一、包封率高、pH响应释放及生物利用度高等特点。动物实验证实，显著优于传统汤剂，且安全性良好，为阴经癌治疗提供了高效低毒的新型中药纳米药物。

一种缓解仔猪肠道氧化损伤的功能性饲料添加剂及其制备方法和应用

Resumen de: CN121242138A

本发明提供了一种缓解仔猪肠道氧化损伤的功能性饲料添加剂及其制备方法和应用，所述功能性饲料添加剂以重量份数计包括植物提取物30‑50份、水翁花多酚‑介孔二氧化硅纳米颗粒0.5‑2份、牡荆苷0.05‑1份和甘蔗多酚1‑3份。本发明提供的产品可缓解仔猪氧化应激造成的肠道结构损伤，保护肠道正常结构与功能；降低炎症因子，改善炎症反应，维护肠道健康；减少仔猪腹泻，提高仔猪的生产性能。

CRYPTOCOCCAL NANO-IMMUNOTHERAPY: A FUNGAL DRUG CARRIER PLATFORM

Resumen de: WO2026006769A1

The present invention provides a fungal drug carrier comprising an avirulent fungal pathogen cell, for example a Cryptococcus neoformans cell, linked to one or more surface-bound drug-loaded nanoparticles, and methods of making the fungal drug carrier. The invention provides methods of using the fungal drug carrier to deliver a drug to the central nervous system of a patient, wherein the fungal drug carrier is phagocytosed by an immune cell of a patient, transported across the blood-brain barrier, and vomocytosed to allow drug release from the surface-bound nanoparticle into the central nervous system of the patient. The methods involve treating a central nervous system in a patient comprising administering to the patient a pharmaceutical composition comprising a fungal drug carrier.

A SYSTEM FOR DELIVERING GENETIC MATERIAL SUBCUTANEOUSLY WITH ELEMENTS ENABLING SUBSEQUENT POST-TREATMENT IDENTIFICATION, LOCALIZATION, QUANTIFICATION, EVALUATION, OR TARGETING FOR UP- AND/OR DOWN-TITRATION

Resumen de: WO2026006281A1

Provided herein is a system for delivering genetical material, preferably subcutaneously, and its various elements. Also provided are related compositions and methods.

ENZYME ENCAPSULATED NANOPARTICLES

Resumen de: WO2026006092A1

Provided herein are compositions, systems, kits, and methods for treating a patient with a disease or condition by administering nanoparticles comprising a biocompatible polymer, wherein the nanoparticles fully, or almost fully, encapsulate: i) tissue-type plasminogen activator (tPA), ii) at least one antioxidant enzyme selected from: superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase, and optionally iii) plasmin protein. In certain embodiments, the disease or condition is selected from: thromboembolism, ischemia-reperfusion injury, stroke, spinal cord injury (SCI), Alzheimer's disease, Muscular Dystrophy, Hypercoagulability, Vaso-occlusive conditions, a fibrotic condition, internal tissue scarring, peritoneal scarring, wound associated scarring, surgical incision associated scarring, and/or dermal scarring.

TRANSITION METAL DICHALCOGENIDE (TMD)-BASED ANTIBODY MIMETIC, IMMUNOTHERAPEUTIC AGENT COMPRISING SAME, AND PREPARATION METHOD THEREFOR

Resumen de: WO2026005574A1

Provided are transition metal dichalcogenide (TMD)-based antibody mimetic comprising: a transition metal dichalcogenide nanosheet; and a tripeptide bound to the nanosheet. The antibody mimetic according to the present invention can strongly bind to PD-L1 with a dissociation constant at the nanomolar level, and can selectively bind to albumin and immunoglobulin (IgG1), which are major plasma proteins, at least 1.5 times more selectively. As a result, imaging of PD-L1-overexpressing cancer cells is possible by treating PD-L1-overexpressing cancer cells with a TMD nanosheet antibody mimic so as to detect the Raman scattering signal, which is an intrinsic optical characteristic of the material. In addition, the PD-L1/PD-1 binding blocking effect of the TMD nanosheet antibody mimetic, according to the present invention, can be identified at the cell level and the cancer cell transplantation animal model level, and thus the TMD nanosheet antibody mimetic can also function as an immunotherapeutic agent.

近红外二区聚集诱导发光纳米粒子实现的协同光动力-光热肿瘤治疗

Resumen de: CN121248630A

本发明公开了一种近红外二区聚集诱导发光纳米粒子实现的协同光动力‑光热肿瘤治疗，属于使用聚集诱导发光材料用于癌症治疗领域。本发明的近红外二区聚集诱导发光的光敏化合物的制备方法包括以下步骤：将化合物1、化合物2、四三苯基膦钯、碳酸钾在四氢呋喃和水的混合溶液中混合，回流反应，得到化合物3；将化合物3和R2在乙酸酐中混合，反应，得到所述近红外二区聚集诱导发光的光敏化合物。本发明通过分子设计，成功制备了一种集NIR‑II激发、高效I型PDT、超高效率PTT及AIE特性于一体的多功能光敏剂，为解决肿瘤治疗中的缺氧瓶颈和实现高效协同治疗提供了一种全新技术方案。

一种提高姜黄素-小米醇溶蛋白纳米颗粒包封率的制备方法

Resumen de: CN121242222A

本发明提供了一种姜黄素‑小米醇溶蛋白‑透明质酸纳米颗粒及其制备方法。具体包括以下几个步骤：（1）负载姜黄素的小米醇溶蛋白‑透明质酸纳米颗粒的制备；（2）透明质酸提高纳米颗粒的包封率。本发明制备的纳米颗粒通过反溶剂沉淀法制备得到，所获的纳米颗粒粒径小且分布均一，稳定性较好，包封率和载药量高。制备体系均为天然来源物质，工艺简单，可以实现小米醇溶蛋白‑透明质酸纳米颗粒的宏量制备，提高疏水性物质的生物利用率，对小米醇溶蛋白的应用具有重要意义。

三螺旋结构元件在RNA药物设计中的应用

Resumen de: CN121249652A

本发明公开了一种三螺旋结构元件在RNA药物设计中的应用，属于生物医药领域。所述应用为：将ENE元件或其突变体作为核酸稳定元件，通过优化3’UTR与poly(A)的相互作用，增强mRNA稳定性并进一步提升蛋白翻译效率，从而有效解决RNA疗法中蛋白表达量低的问题。本发明提出的mRNA序列优化策略为传染病及肿瘤免疫治疗领域的疫苗设计提供了新方法，具有广泛的应用前景。

一种女性更年期调理用精油组合物及其制备工艺

Resumen de: CN121243285A

本发明提供一种女性更年期调理用精油组合物及其制备工艺，属于调理更年期精油技术领域；其制备方法包括：制备黑升麻提取物纳米复合物；制备复合精油微胶囊；制备精油组合物。本发明通过将乳清分离蛋白和羧甲基淀粉钠分别溶解后，再加热搅拌混合，使二者通过静电吸引初步结合，再加入复配精油，经均质和超声波处理制成复合乳液后，能够显著增加微胶囊的比表面积，提供更多吸附位点，然后通过转谷氨酰胺酶催化乳清分离蛋白分子间谷氨酰胺与赖氨酸的交联反应，形成三维网络骨架，同时羧甲基淀粉钠的羧基可通过离子键与乳清分离蛋白的氨基结合，填充网络间隙，从而能够有效提升对复配精油的包埋率。

一种具有疫苗免疫增强作用的蒲公英多糖PLGA纳米颗粒的制备方法

Resumen de: CN121243366A

本发明涉及生物药品制造领域，具体为一种具有疫苗免疫增强作用的蒲公英多糖PLGA纳米颗粒的制备方法，所述蒲公英多糖PLGA纳米颗粒的平均粒度为80‑120 nm，Zeta电势为‑35.5±0.5mV，包封率≥84%，24 h释放率≥83%。本方案制得了包封率≥84%，载药量≥4.5%，24 h释放率≥83%且能够稳定储存的蒲公英多糖PLGA纳米颗粒，能够应用于疫苗药物，具有疫苗免疫增强作用。

一种预防白内障、黄斑病变和糖网病变的组合物以及制备方法和应用

Resumen de: CN121243255A

本发明提供了一种预防白内障、黄斑病变和糖网病变的组合物以及制备方法和应用，属于生物医药技术领域。本发明组合物，包括：纳米活性成分、植萃提取物、甘草酸二钾、烟酰胺、牛磺酸、依克多因、咖啡因和叶黄素；植萃提取物由野菊花提取物和龙胆提取物组成；纳米活性成分由纳米包裹虾青素和纳米视黄醇组成。本发明组合物通过抗氧化‑抗炎‑血管保护‑代谢调节的多维协同机制，有效抑制晶状体蛋白氧化变性、视网膜色素上皮细胞功能衰退及病理性血管生成等关键病理环节，从而实现对白内障、年龄相关性黄斑变性与糖尿病视网膜病变三种主要致盲眼病的预防与辅助治疗作用。

吸入药物组合物

Resumen de: AU2024279267A1

Disclosed is a pharmaceutical composition for inhalation, comprising lipid carriers comprising a pharmaceutical agent, the therapeutic uses thereof, and a method of making same.

用于递送核酸和其他治疗剂的含硫的可电离脂质

Resumen de: AU2023407128A1

Provided herein is an ionizable, cationic amino lipid or a pharmaceutically acceptable salt thereof. The ionizable, cationic amino lipid has: a protonatable amino head group; two lipophilic chains, wherein the protonatable amino head group has a central carbon atom to which each of the two lipophilic chains are directly bonded; at least one of the two lipophilic chains has a structure of Formula C: Formula C wherein E is an ester in either orientation. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.

含可裂解接头的可电离脂质和用于治疗性组合物的脂质载体

Resumen de: TW202438045A

The present disclosure relates to a lipid compound of formula (AL-GI):, having various cleavable linkers defined by the variables Z1 and Z2. The present disclosure also relates to a lipid carrier or lipid nanoformulation employing the lipid compound, and the use of the lipid compound in a pharmaceutical composition as well as for a method of delivering a therapeutic agent.

纳米颗粒组合物及相关方法

Resumen de: WO2024253582A1

There is provided a nanoparticle composition comprising a compound represented by general formula (1) or ionized form thereof, wherein R1, R2, and R4 to R8 are each independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, R3 is optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene, and R9 and R10 are each independently a hydrophobic tail or contains at least one of the groups defined above for R4 to R8; a therapeutic, prophylactic, and/or biological agent that is encapsulated by the compound of general formula (1) to form nanoparticles; and a cryoprotectant. There is also provided a method of preparing said nanoparticle composition.

一种基于N-乙酰半胱氨酸的可电离脂质、脂质纳米粒及制备方法与应用

Resumen de: CN121248455A

本发明提供一种基于N‑乙酰半胱氨酸的可电离脂质、脂质纳米粒及制备方法与应用。本发明所提供的全新结构的可电离脂质，其可形成粒径均一、结构稳定的LNP，转染效率高且生物相容性好。此外，所制备的LNP具有低免疫原性，能够引起免疫细胞(如巨噬细胞、树突状细胞)较低共刺激分子的表达。

CONICAL SHAPED DIACYL GLYCEROETHYLPHOSPHOCHOLINES AS CATIONIC LIPIDS AND USES THEREOF

Resumen de: WO2026006196A1

A compound having the structure (I) is provided. The compound is useful as a therapeutic agent in the form of a lipoplex, or in a form of a polyplex, in a form of a lipid nanoparticle, or in a form of a liposome, or in a form of a micelle, or in a form of an emulsion including a drug, vaccine, oligonucleotide, antibody, enzyme, protein, small molecule, or nucleotide.

TARGETED POLYMERIC NANOPARTICLES LOADED WITH DUAL THERAPEUTIC AGENTS AND METHODS THEREOF

Resumen de: WO2026006790A2

Provided herein are nanoparticles comprising a triblock copolymer and a targeting moiety for targeted delivery of one or more therapeutic agents, and formulations thereof. Also provided herein are layered drug delivery vehicles. Further provided herein are methods, or uses thereof, for treating cancers, preferably pancreatic and brain cancers, by administration of the nanoparticles disclosed herein.

PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS, AND METHODS OF MAKING AND USING SAME

Resumen de: WO2026006759A1

Pharmaceutical compositions of Compound (I) including solid dispersions of Compound (I) and nanocrystalline powder forms of Compound (I). Related unit dosage forms, and methods of making and using the same are also provided.

METHOD FOR PRODUCING LIPID NANOPARTICLES

Nº publicación: WO2026006555A1 02/01/2026

Solicitante:

SIGMA ALDRICH CO LLC [US]
SIGMA-ALDRICH CO. LLC